Drug class
Oral non-peptide somatostatin receptor 2 (SSTR2) agonist; acromegaly therapy
Mechanism of action
Activates somatostatin receptor 2 on pituitary somatotroph cells, reducing growth hormone secretion and downstream circulating insulin-like growth factor-1 (IGF-1).
General use cases
- Treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option under the US PALSONIFY indication (approved 25 September 2025)
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
